The World Health Organisation has cleared the use of drugs like Ozempic for weight loss. WHO has released its first guideline on GLP-1 therapies for obesity, as global demand for the medication surges and the market heads toward nearly $49 billion by 2030. The organisation has flagged high costs, limited long-term safety data, supply gaps and a rise in falsified products, urging stronger regulation and fair access. The move marks a major shift in global obesity policy, recognising the condition

Fat cat Ozempic might have arrived. Here's what one Bay Area based company is doing to slim down household pets with a new GLP-1 implant clinical weight loss study for cats called MEOW-1. | ABC7 News